Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amezalpat (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; IO-108 (Primary) ; Muzastotug (Primary) ; NKT 2152 (Primary) ; Tiragolumab (Primary) ; Tobemstomig (Primary) ; Tocilizumab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms Morpheus-Liver
Sponsors Roche

28 Feb 2025 According to a Immune-Onc Therapeutics media release, company is expected to enroll 40 patients across 25 sites worldwide in the IO-108-containing arm.
28 Feb 2025 According to a Immune-Onc Therapeutics media release, the first patient has been dosed with IO-108 in a global clinical collaboration with Roche.
21 Jan 2025 According to a NiKang Therapeutics media release, first patient has been dosed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com